SCI Pharmtech Inc (4119) - Total Assets
Based on the latest financial reports, SCI Pharmtech Inc (4119) holds total assets worth NT$6.85 Billion TWD (≈ $215.91 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 4119 book value for net asset value and shareholders' equity analysis.
SCI Pharmtech Inc - Total Assets Trend (2002–2024)
This chart illustrates how SCI Pharmtech Inc's total assets have evolved over time, based on quarterly financial data.
SCI Pharmtech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SCI Pharmtech Inc's total assets of NT$6.85 Billion consist of 23.1% current assets and 76.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 8.1% |
| Accounts Receivable | NT$289.51 Million | 4.0% |
| Inventory | NT$620.90 Million | 8.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$37.77 Million | 0.5% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2024)
This chart illustrates how SCI Pharmtech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SCI Pharmtech Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCI Pharmtech Inc's current assets represent 23.1% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, up from 0.1% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 8.6% of total assets.
SCI Pharmtech Inc Competitors by Total Assets
Key competitors of SCI Pharmtech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥1.91 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥2.64 Billion |
SCI Pharmtech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 2.35 | 1.71 |
| Quick Ratio | 0.38 | 1.68 | 1.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$96.94 Million | NT$1.23 Billion | NT$796.60 Million |
SCI Pharmtech Inc - Advanced Valuation Insights
This section examines the relationship between SCI Pharmtech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.19 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | NT$7.20 Billion |
| Market Capitalization | $175.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values SCI Pharmtech Inc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SCI Pharmtech Inc's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SCI Pharmtech Inc (2002–2024)
The table below shows the annual total assets of SCI Pharmtech Inc from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$7.20 Billion ≈ $226.86 Million |
+7.62% |
| 2023-12-31 | NT$6.69 Billion ≈ $210.80 Million |
+34.88% |
| 2022-12-31 | NT$4.96 Billion ≈ $156.28 Million |
+18.39% |
| 2021-12-31 | NT$4.19 Billion ≈ $132.00 Million |
-8.32% |
| 2020-12-31 | NT$4.57 Billion ≈ $143.98 Million |
+11.97% |
| 2019-12-31 | NT$4.08 Billion ≈ $128.59 Million |
+7.72% |
| 2018-12-31 | NT$3.79 Billion ≈ $119.38 Million |
+14.97% |
| 2017-12-31 | NT$3.30 Billion ≈ $103.83 Million |
-7.17% |
| 2016-12-31 | NT$3.55 Billion ≈ $111.86 Million |
+2.70% |
| 2015-12-31 | NT$3.46 Billion ≈ $108.92 Million |
+7.33% |
| 2014-12-31 | NT$3.22 Billion ≈ $101.48 Million |
+5.51% |
| 2013-12-31 | NT$3.05 Billion ≈ $96.17 Million |
+92.83% |
| 2012-12-31 | NT$1.58 Billion ≈ $49.87 Million |
+4.39% |
| 2011-12-31 | NT$1.52 Billion ≈ $47.78 Million |
+0.79% |
| 2010-12-31 | NT$1.50 Billion ≈ $47.40 Million |
+20.16% |
| 2009-12-31 | NT$1.25 Billion ≈ $39.45 Million |
+10.55% |
| 2008-12-31 | NT$1.13 Billion ≈ $35.69 Million |
+6.57% |
| 2007-12-31 | NT$1.06 Billion ≈ $33.49 Million |
+21.90% |
| 2006-12-31 | NT$871.95 Million ≈ $27.47 Million |
-2.70% |
| 2004-12-31 | NT$896.13 Million ≈ $28.23 Million |
+4.98% |
| 2003-12-31 | NT$853.62 Million ≈ $26.89 Million |
+6.20% |
| 2002-12-31 | NT$803.82 Million ≈ $25.32 Million |
-- |
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more